All In Biotech

Drug Trial Radar · NCT05327010

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Nov 14, 2022

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
NIH
First posted
Apr 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Another aim of this study is to find out if, and how, patients' genes influence their response to this specific drug combination. For this part of the study, investigators will run tests using samples of patients' tumor tissue and blood that will be collected during the study. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Genes are pieces of the DNA code that individuals inherit from their parents. Some genes work to protect against cancer by correcting damage that can occur in the DNA when cells divide. BRCA1 and BRCA2 are two examples of these types of genes, and they are called tumor-suppressor genes. For example, if a person has a mutation in a BRCA1/2 gene they have a greatly increased risk of developing breast and ovarian cancer because their cells may no longer be able to completely repair damaged DNA. It is the accumulation of DNA damage which causes a cell to change into a cancerous cell. Other genes are also involved in this process, and these are called DNA damage repair genes. The KRAS mutation is a change in a protein in normal cells. Normally KRAS serves as an information hub for signals in the cell that lead to cell growth, but when there is a mutation in KRAS it signals too much and cells grow without being told to, which causes cancer. Combination therapy with ZEN-3694 and talazoparib may be effective at slowing or stopping tumor growth in patients with advanced cancer.

Conditions

  • Advanced Malignant Solid Neoplasm
  • Metastatic Malignant Solid Neoplasm
  • Unresectable Malignant Solid Neoplasm

Interventions

  • BET Bromodomain Inhibitor ZEN-3694Drug

    Given PO

  • Biopsy ProcedureProcedure

    Undergo tumor biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Diagnostic Imaging TestingProcedure

    Undergo diagnostic imaging

  • TalazoparibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: From initiation of treatment to first response

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • City of Hope at Irvine Lennar

    Irvine, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Keck Medicine of USC Koreatown

    Los Angeles, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • UCHealth University of Colorado Hospital

    Aurora, Colorado

  • Yale University

    New Haven, Connecticut

  • Smilow Cancer Hospital Care Center-Trumbull

    Trumbull, Connecticut

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Kansas Clinical Research Center

    Fairway, Kansas

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • University of Kansas Cancer Center-Overland Park

    Overland Park, Kansas

  • University of Kansas Hospital-Indian Creek Campus

    Overland Park, Kansas

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky

  • Ochsner Medical Center Jefferson

    New Orleans, Louisiana

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

  • University of Kansas Cancer Center - North

    Kansas City, Missouri

  • University of Kansas Cancer Center - Lee's Summit

    Lee's Summit, Missouri

  • University of Kansas Cancer Center at North Kansas City Hospital

    North Kansas City, Missouri

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • University of Texas at Austin

    Austin, Texas

  • University of Texas Medical Branch

    Galveston, Texas

  • UT MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah

  • University of Virginia Cancer Center

    Charlottesville, Virginia

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.